CDKN2A and neoplasm: Interestingly, loss-of-function mutations in TP53, CDKN2A or in the polycomb repressive complex 2 (PRC2), an epigenetic regulator associated with EMT in other contexts and tumour types [154–156], trigger PN progression into MPNST [157–160].